Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization

類似資料

• Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test
  著者:: E. V. Grakova, 等
  出版事項: (2019-09-01)
• Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction
  著者:: E. V. Grakova, 等
  出版事項: (2022-04-01)
• Coronary flow reserve in patients with heart failure with preserved ejection fraction
  著者:: A. V. Mochula, 等
  出版事項: (2022-03-01)
• Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization
  著者:: Pyka, Łukasz, 等
  出版事項: (2017)
• Prognosis of cardiovascular events after implantation of a cardioverterdefibrillator in patients with chronic heart failure: the value of increasing concentration of endothelin-1 and soluble forms of ST2 protein in blood plasma
  著者:: A. T. Teplyakov, 等
  出版事項: (2018-09-01)